Anthropic’s IPO Clarification Dashes Investor Frenzy, Redefining Early-Stage Valuations

Anthropic has recently cooled the enthusiasm of investors eager to join early.

This leading AI company has imposed strict limits on over-the-counter stock trading, clearly stating that any share transfer without board approval will not be recognized. Furthermore, its official support page explicitly named several secondary markets and private platforms, declaring that Anthropic shares or related rights traded there are unauthorized. Such transactions may be deemed invalid, and shareholder registers will not be updated.

This news has immediately sparked tension within investor circles. Bloomberg reported that in a WhatsApp group with hundreds of family office members, someone bluntly asked: "Are we doomed?"

Underlying this is a mismatch of expectations in the current AI valuation frenzy.

As one of the most closely watched companies in the large model race, Anthropic is already considered "essential" by the market, despite not being publicly traded. However, ordinary investors cannot buy shares of unlisted companies. Consequently, various "workarounds" have emerged, including special purpose vehicles (SPVs), secondary market share transfers, forward contracts, nominee structures, and financial products claiming to offer "indirect equity" in hot AI firms.

These transactions cater to the fear of missing out: by the time the company goes public, shares might be too expensive; investing now is seen as securing a future opportunity.

From the company's perspective, however, the logic is entirely different.

Especially when valuations are soaring and an IPO seems likely, companies like Anthropic must strictly control their shareholder structure, transfer paths, and information disclosure. If the external market overhypes "shadow rights," it could disrupt corporate governance and create compliance risks and reputational damage.

Thus, this reaffirmation of rules is essentially a "boundary clarification": you may believe you've purchased an early ticket to an AI unicorn, but the company may not recognize its validity.

This is harsh for investors, as the appeal of many pre-IPO transactions lies in the promise of "locking in listing gains." Once the company declares unapproved rights invalid, those who invested through complex structures may realize: what they hold is not a stock, but a contract with significant ambiguity and an unclear redemption path.

This explains the anxiety in investor groups. The higher the valuation of AI companies, the more people want early access; the more people use alternative routes, the tighter the company's boundaries become. The result: the hottest assets have become the most opaque and difficult to verify.

Looking at the broader industry, this incident highlights an awkward reality: the market has already priced top AI companies as the "next internet," yet their business models, revenue streams, and cost structures remain unproven. Computing costs are skyrocketing, income is unpredictable, and industry consolidation is far from complete. In this context of high valuations and low transparency, a collective illusion of FOMO prevails, even if no one fully understands the situation.

Even more concerning is that as the wealth glow of AI unicorns spills from primary markets to attract ordinary investors, the information asymmetry gap widens. Ordinary investors often bear the highest risks without basic protections. Even if the equity transfer itself is valid, the underlying assets remain highly uncertain.